CymaBay Names Lewis Stuart Chief Commercial Officer
10 mai 2021 08h00 HE
|
CymaBay Therapeutics, Inc.
Proven Leader in Building Commercial Organizations to Prepare Markets and Deliver Successful Product Launches Planning for Seladelpar Launch as it Completes Development and Regulatory Submissions ...
CymaBay Therapeutics to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
06 mai 2021 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of Directors
05 avr. 2021 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update
25 mars 2021 16h10 HE
|
CymaBay Therapeutics, Inc.
Actively recruiting patients in two global, clinical studies evaluating seladelpar in primary biliary cholangitis (PBC): RESPONSE, a 52-week, randomized, placebo-controlled, Phase 3 registrational...
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021
12 mars 2021 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics to Present at the 2021 NASH-TAG Conference
11 mars 2021 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics to Present at Upcoming Investor Conferences
24 févr. 2021 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference
10 févr. 2021 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics Announces Oral Late-Breaking Presentation of Positive Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020
16 nov. 2020 16h01 HE
|
CymaBay Therapeutics, Inc.
Seladelpar demonstrated anti-cholestatic, anti-inflammatory, and anti-pruritic activity through 3 and 6 monthsResults highlight the potential for seladelpar to offer patients an efficacious and safe...
CymaBay Therapeutics to Present at Upcoming Investor Conferences
11 nov. 2020 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...